Legend Biotech Corporation
LEGN
$19.91
-$0.58-2.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.90% | 56.46% | 59.12% | 70.28% | 38.57% |
| Total Other Revenue | -- | -- | 98.16% | -93.59% | -99.88% |
| Total Revenue | 51.90% | 56.46% | 64.21% | 69.99% | 36.77% |
| Cost of Revenue | 40.20% | 146.70% | 66.97% | 107.87% | 94.25% |
| Gross Profit | 59.20% | 4.45% | 62.39% | 49.92% | 15.45% |
| SG&A Expenses | 19.45% | 24.28% | 21.68% | 9.75% | 23.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 220.00% | -- | -- | -- |
| Total Operating Expenses | 19.06% | 43.86% | 25.04% | 36.96% | 21.23% |
| Operating Income | 363.47% | 3.68% | 72.50% | 38.24% | 47.82% |
| Income Before Tax | 144.47% | 46.47% | -148.34% | 67.68% | -594.49% |
| Income Tax Expenses | 3,616.67% | -33.33% | -21.20% | -86.11% | 165.49% |
| Earnings from Continuing Operations | 126.48% | 46.24% | -217.12% | 68.33% | -589.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 126.48% | 46.24% | -217.12% | 68.33% | -589.16% |
| EBIT | 363.47% | 3.68% | 72.50% | 38.24% | 47.82% |
| EBITDA | 414.80% | 4.05% | 75.18% | 40.00% | 49.52% |
| EPS Basic | 126.06% | 46.63% | -216.24% | 68.56% | -583.73% |
| Normalized Basic EPS | 143.79% | 46.86% | -145.43% | 67.90% | -588.78% |
| EPS Diluted | 126.06% | 45.42% | -225.92% | 67.83% | -581.00% |
| Normalized Diluted EPS | 142.26% | 46.86% | -149.89% | 67.90% | -588.78% |
| Average Basic Shares Outstanding | 1.55% | 0.73% | 0.77% | 0.74% | 0.85% |
| Average Diluted Shares Outstanding | 5.24% | 0.73% | -8.28% | 0.74% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |